BlossomHill doses first patient in SOLARA study’s expansion cohorts
BlossomHill Therapeutics has dosed the first subject in the expansion cohorts of the SOLARA Phase I/II trial to evaluate BH-30643 …
Post
-
-
Lighthouse secures $49.2m NIA grant for Alzheimer’s therapy trial
Lighthouse Pharmaceuticals has secured a grant of $49.2m from the National Institute on Aging (NIA), a division of the National …
-
Animal testing alternatives to dominate, but not overnight
In a bid to prioritise more human-relevant models, the US Food and Drug Administration (FDA) has enforced a plan to …
-
AbbVie seeks Rinvoq alopecia approval after second Phase III success
AbbVie’s star Janus kinase (JAK) inhibitor, Rinvoq (upadacitinib), has met its primary endpoints in a second Phase III study in …
-
Navigating regulatory change in APAC: Insights from the upcoming BioSecure Act Webinar
The regulatory landscape across the Asia-Pacific (APAC) region is evolving rapidly, and pharmaceutical companies must adapt to maintain compliance, mitigate …
-
Dynavax’s shingles vaccine shows promise in trial against GSK’s Shingrix
Dynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, comparing its shingles …
-
Tyra Biosciences initiates paediatric study for achondroplasia treatment
US-based Tyra Biosciences has dosed the first paediatric participant in the dose-escalation/dose-expansion Phase II BEACH301 trial designed to assess the …
-
Padcev-Keytruda combo approved for NHS use in mUC
The UK’s National Institute for Health and Care Excellence (NICE) has recommended a new combination regimen in metastatic urothelial carcinoma …
-
Advancing rare disease trials by overcoming patient recruitment challenges
In September 2025, clinical development and clinical operations professionals will gather and discuss the current challenges in running clinical trials …
-
Scipher Medicine introduces AI platform to forecast trial failure
Precision immunology company Scipher Medicine has introduced the ClinicalTrialRank.com AI platform to the public, designed to forecast the likelihood of …
-
Rocket to relaunch rare disease trial after FDA approval
The US Food and Drug Administration (FDA) has given Rocket Pharmaceuticals approval to continue its pivotal Phase II trial of …
-
Neurizon’s ALS expansion data supports NUZ-001 advancement to HEALEY trial
Neurizon Therapeutics’ disease-modifying drug NUZ-001 has been shown to be safe and effective over 2.5 years of dosing in patients …
-
Hutchmed finalises subject enrolment for Orpathys and Tagrisso combo trial
Hutchmed has completed subject enrolment in the randomised Phase III SANOVO trial in China, which is evaluating the combination of …
-
Uncertainty remains over FDA block on China engineering of US cells
The impact of a recent US Food and Drug Administration (FDA) ruling barring new clinical trials that involve sending US …
-
MTPA’s Radicava shows long-term benefit in ALS trials
Mitsubishi Tanabe Pharma America’s (MTPA) oral therapy Radicava (edaravone) has shown decreased functional decline and improved survival in long-term amyotrophic …
